Browse Arkansas Code titles and sections
21 U.S.C. § 829a — Delivery of a controlled substance by a pharmacy to an administering practitioner
Federal law — U.S. Code and appendices · legal_authorities
**(a) In general** Notwithstanding [section 802(10) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section802/10&num=0&edition=prelim), a pharmacy may deliver a controlled substance to a practitioner in accordance with a prescription that meets the requirements of this subchapter and the regulations issued by the Attorney General under this subchapter, for the purpose of administering the controlled substance by the practitioner if—
(1) the controlled substance is delivered by the pharmacy to the prescribing practitioner or the practitioner administering the controlled substance, as applicable, at the location listed on the practitioner’s certificate of registration issued under this subchapter;
(2) the controlled substance is a drug in schedule III, IV, or V to be administered—
(A) by injection or implantation for the purpose of maintenance or detoxification treatment; or
(B) subject to a risk evaluation and mitigation strategy pursuant to [section 355–1 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355-1&num=0&edition=prelim) that includes elements to assure safe use of the drug described in subsection (f)(3)(E) of such section, including a requirement for post-administration monitoring by a health care provider;
(3) the pharmacy and the practitioner are authorized to conduct the activities specified in this section under the law of the State in which such activities take place;
(4) the prescription is not issued to supply any practitioner with a stock of controlled substances for the purpose of general dispensing to patients;
(5) except as provided in subsection (b), the controlled substance is to be administered only to the patient named on the prescription not later than 45
Source: Supplied U.S. Code snapshot — release unconfirmed · 21 U.S.C. § 829a
Stored review status: release_metadata_unconfirmed. A text match is a research starting point; applicability is not established.
Original supplied file — preserved unchanged
Download original Markdown file
File SHA-256: ebbafcc5086e0ce6a3059bb137fef670cb423acc28f4cf94fb3316dc762cc7d5. The original may include catalog metadata, neighboring provisions, or embedded records outside this collection's scope. Search shows only the selected federal record. Historical editions and unverified snapshots are not a statement of current law.
Authority boundary: historical or unconfirmed source not current law verified.
Open the recorded source website ↗
Record provenance
Stable record: federal_law:legal_authorities:record_usc_63256ca00d6da38d5c1eb08b
Source file: Laws/federal/codes/united-states-code/title-21/section-829a-delivery-of-a-controlled-substance-by-a-pharmacy-to-an-administering-pra--12444aef62.md
Pages: Not recorded – Not recorded
Passage SHA-256: 70049d8fabff4224a201928ef838f4be0c7f486ce23266452f6b5a52b16124fe
Source location: Title 21, Chapter 13, § 829a; chapter-013-drug-abuse-prevention-and-control.md
Stored source content
**(a) In general** Notwithstanding [section 802(10) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section802/10&num=0&edition=prelim), a pharmacy may deliver a controlled substance to a practitioner in accordance with a prescription that meets the requirements of this subchapter and the regulations issued by the Attorney General under this subchapter, for the purpose of administering the controlled substance by the practitioner if—
(1) the controlled substance is delivered by the pharmacy to the prescribing practitioner or the practitioner administering the controlled substance, as applicable, at the location listed on the practitioner’s certificate of registration issued under this subchapter;
(2) the controlled substance is a drug in schedule III, IV, or V to be administered—
(A) by injection or implantation for the purpose of maintenance or detoxification treatment; or
(B) subject to a risk evaluation and mitigation strategy pursuant to [section 355–1 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355-1&num=0&edition=prelim) that includes elements to assure safe use of the drug described in subsection (f)(3)(E) of such section, including a requirement for post-administration monitoring by a health care provider;
(3) the pharmacy and the practitioner are authorized to conduct the activities specified in this section under the law of the State in which such activities take place;
(4) the prescription is not issued to supply any practitioner with a stock of controlled substances for the purpose of general dispensing to patients;
(5) except as provided in subsection (b), the controlled substance is to be administered only to the patient named on the prescription not later than 45 days after the date of receipt of the controlled substance by the practitioner; and
(6) notwithstanding any exceptions under [section 827 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section827&num=0&edition=prelim), the prescribing practitioner, and the practitioner administering the controlled substance, as applicable, maintain complete and accurate records of all controlled substances delivered, received, administered, or otherwise disposed of under this section, including the persons to whom controlled substances were delivered and such other information as may be required by regulations of the Attorney General.
**(b) Modification of number of days before which controlled substance shall be administered**
(1) **Initial 2-year period** — During the 2-year period beginning on October 24, 2018, the Attorney General, in coordination with the Secretary, may reduce the number of days described in subsection (a)(5) if the Attorney General determines that such reduction will—
(A) reduce the risk of diversion; or
(B) protect the public health.
(2) **Modifications after submission of report** — After the date on which the report described in section 3204(b) of the SUPPORT for Patients and Communities Act is submitted, the Attorney General, in coordination with the Secretary, may modify the number of days described in subsection (a)(5).
(3) **Minimum number of days** — Any modification under this subsection shall be for a period of not less than 7 days.
Cross-references
Connections may be documented source relationships, shared citations or nearby passages. Each explains its basis; a connection alone does not establish applicability to your situation.
Federal law — U.S. Code and appendices · legal_authorities
**(a) Inventory** Except as provided in subsection (c)—
(1) every registrant under this subchapter shall, on May 1, 1971, or as soon thereafter as such registrant first engages in the manufacture, distribution, or dispensing of controlled substances, and every second year thereafter, make a complete and accurate record of all stocks thereof on hand, except that the regulations prescribed under this section shall permit each such biennial inventory (following the initial inventory required by this paragraph) to be prepared on such registrant’s regular general physical inventory date (if any) which is nearest to and does not vary by more than six months from the biennial date that would otherwise apply;
(2) on the effective date of each regulation of the Attorney General controlling a substance that immediately prior to such date was not a controlled substance, each registrant under this subchapter manufacturing, distributing, or dispensing such substance shall make a complete and accurate record of all stocks thereof on hand; and
(3) on and after May 1, 1971, every registrant under this subchapter manufacturing, distributing, or dispensing a controlled substance or substances shall maintain, on a current basis, a complete and accurate record of each such substance manufactured, received, sold, delivered, or otherwise disposed of by him, except that this paragraph shall not require the maintenance of a perpetual inventory.
**(b) Availability of records** Every inventory or other record required under this section (1) shall be in accordance with, and contain such relevant information as may be required by, regulations of the Attorney General, (2) shall (A) be maintained separately from all other records of the registrant, or (B) alternatively, in the case of nonnarcoti
Source: Supplied U.S. Code snapshot — release unconfirmed · 21 U.S.C. § 827
Stored review status: release_metadata_unconfirmed. Explicit cross-reference supplied in source Markdown; currentness and applicability require review.
Federal law — U.S. Code and appendices · legal_authorities
Page 831
TITLE 21—FOOD AND DRUGS
§ 829a
missioner of Food and Drugs, Director of the Centers
for Disease Control and Prevention, and Assistant Sec-
retary for Mental Health and Substance Use, shall de-
velop and disseminate not later than 1 year after the
date of enactment of the Restoring Hope for Mental
Health and Well-Being Act of 2022 [Dec. 29, 2022], and
update periodically thereafter, as appropriate, mate-
rials for pharmacists, health care providers, and pa-
tients on—
‘‘(1) circumstances under which a pharmacist may,
consistent with section 309 of the Controlled Sub-
stances Act (21 U.S.C. 829) and regulations there-
under, including section 1306.04 of title 21, Code of
Federal Regulations, decline to fill a prescription for
a controlled substance because the pharmacist sus-
pects the prescription is fraudulent, forged, or of
doubtful, questionable, or suspicious origin; and
‘‘(2) other Federal requirements pertaining to de-
clining to fill a prescription under such cir-
cumstances, including the partial fill of prescriptions
for certain controlled substances.
‘‘(b) MATERIALS INCLUDED.—In developing materials
under subsection (a), the Secretary of Health and
Human Services shall include information for—
‘‘(1) pharmacists on how to verify the identity of
the patient;
‘‘(2) pharmacists on how to decline to fill a pre-
scription and actions to take after declining to fill a
prescription; and
‘‘(3) other health care practitioners and the public
on a pharmacist’s ability to decline to fill prescrip-
tions in certain circumstances and a description of
those circumstances (as described in the materials
developed under subsection (a)(1)).
‘‘(c) STAKEHOLDER
INPUT.—In developing the pro-
grams and materials required under subsection (a), the
Secreta
Source: Supplied 2024 U.S. Code historical extraction · 21 U.S.C. § 829a
Stored review status: historical_2024_not_currentness_verified. Same stored citation; legal effect and authority still require review.